Fatigue assessment when treatment is started may be an early clinical marker of adverse event risk, the researchers suggested ...

Johnson & Johnson (NYSE: JNJ) (the "Company") today announced the successful completion of its acquisition of Halda Therapeutics OpCo, Inc. ("Halda"), a clinical-stage biotechnology company with a ...

One of the most challenging moments in cancer treatment comes when a therapy stops working. In many metastatic cancers, drugs ...

Chandigarh: As Punjab ages faster than most Indian states, new research has underlined an urgent need for focused cancer ...

Men with the highest lycopene intake had nearly half the risk of developing prostate cancer compared with those in the lowest ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

Here are the top 5 stories from 2025 about the advancements in prostate, kidney, and bladder cancers.

A published case series reports unexpected cancer remissions linked with fenbendazole use, prompting renewed discussion on ...

The Institute of Cancer Research has led a study showing that chromosomal instability in circulating tumour cells can predict resistance to cabazitaxel in men with advanced prostate cancer. Using ...

Gleason grading remains the cornerstone of prostate cancer risk stratification, yet paradoxes persist. Two men with the same absolute volume of Gleason pattern 4 (GP4) can be assigned to different ...

Former President Joe Biden finished his first round of radiation therapy for aggressive prostate cancer on Monday. Biden rang a celebratory bell to commemorate finishing five weeks of the treatment at ...